In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

The vast majority of drugs fail in human trials due to the poor predictivity of preclinical models. Traditional models – whether simple cell cultures in petri dishes or animal models – often fail to ...

As with its predecessor, the new drug candidate, Jun13296, targets a different viral protein than Paxlovid does and works alone rather than in combination with another drug called ritonavir. But ...

"These results not only confirm in-vitro observations in aggressive, androgen-independent human prostate cancer cells but also represent a game-changing discovery in animal models. We are seeing a ...

The drug also significantly reduced inflammation and viral levels ... Most promising is that Jun13296 worked at comparable or lower doses than Paxlovid in similar animal models. “If you look at the ...